Association of CYP2C19 Polymorphisms with Survival of Breast Cancer Patients Using Tamoxifen: Results of a Meta-analysis

  • Bai, Lan (Department of Pharmacy, Kunming General Hospital of Chengdu Military Command) ;
  • He, Juan (Department of Pharmacy, Kunming General Hospital of Chengdu Military Command) ;
  • He, Gong-Hao (Department of Pharmacy, Kunming General Hospital of Chengdu Military Command) ;
  • He, Jian-Chang (Department of Pharmacy, Kunming General Hospital of Chengdu Military Command) ;
  • Xu, Fan (Department of Ophthalmology, People's Hospital of Guangxi Zhuang Autonomous Region) ;
  • Xu, Gui-Li (Department of Pharmacy, Kunming General Hospital of Chengdu Military Command)
  • Published : 2014.10.23


Background: Previous studies accessing the association of CYP2C19 with outcomes of patients using tamoxifen for breast cancer have yielded conflicting results. The aim of this meta-analysis is to obtain a more precise estimate of effects of CYP2C19 polymorphisms and to clarify their effects on survival of the breast cancer patients using tamoxifen. Materials and Methods: A systematic search of PubMed and Embase was performed, comparing patients with or without $CYP2C19^*2$ and $CYP2C19^*17$, relevant articles searched for. The following outcomes were included from the eligible studies: disease-free survival (DFS) and overall survival (OS), expressed by hazard ratios (HR) with corresponding 95% confidence interval (CI). Subgroup analysis by genotypes was also performed. Pooled estimates were calculated using random-effect model in accordance to the heterogeneity. Results: Six studies met the inclusion criteria. The integrated OR on the association between CYP2C19 and DFS, calculated by the random-effect model, was 0.54 (95%CI=0.34-0.84, p=0.013). Subgroup analysis showed that both $CYP2C19^*2$ and $CYP2C19^*17$ were associated with increased survival. The pooled results of two studies for OS were OR=0.46 (95%CI=0.21-1.01, p=0.233). Conclusions: This meta-analysis suggests that the $CYP2C19^*2$ and $CYP2C19^*17$ genotypes are associated with increased survival in breast cancer patients using tamoxifen.


Breast cancer;$CYP2C19^*2$;$CYP2C19^*17$;survival;tamoxifen;meta-analysis


  1. Desta Z, Ward BA, Soukhova NV, et al (2004). Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther, 310, 1062-75.
  2. Beelen K, Opdam M, Severson TM, et al (2013). CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Res Treat, 139, 649-55.
  3. Boocock DJ, Brown K, Gibbs AH, et al (2002). Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis, 23, 1897-1901.
  4. Crewe HK, Notley LM, Wunsch RM, et al (2002). Metabolism of tamoxifen by recombinant human cytochrome p450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and n-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos, 30, 869-74.
  5. Chamnanphon M, Pechatanan K, Sirachainan E, et al (2013). Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmagenomics Pers Med, 6, 37-48.
  6. Colleoni M, Gelber S, Goldhirsch A, et al (2006). Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol, 24, 1332-41.
  7. Darakhshan S, Bidmeshkipour A, Khazaei M, et al (2013). Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev, 14, 6869-74.
  8. Fisher B, Costantino JP, Wickerham DL, et al (2005). Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst, 97, 1652-62.
  9. Gan CQ, Wang XY, Cao YD, et al (2011). Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women. GMR, 10, 3514-19.
  10. Gjerde J, Geisler J, Lundgren S, et al (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer, 10, 313.
  11. Jin Y, Desta Z, Stearns V, et al (2005). CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst, 97, 30-9.
  12. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  13. Ibrahim NI, Dahlui M, Aina EN, et al (2012). Who are the breast cancer survivors in Malaysia? Asian Pac J Cancer Prev, 13, 2213-18.
  14. Johnson MD, Zuo H, Lee KH, et al (2004). Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat, 85, 151-9.
  15. Justenhoven C, Hamann U, Pierl CB, et al (2009). CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat, 115, 391-6.
  16. Li-Wan-Po A, Girard T, Farndon P, et al (2010). Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol, 69, 222-30.
  17. Lu WJ, Xu C, Pei Z, et al (2012). The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat, 133, 99-109.
  18. Lim JS, Chen XA, Singh O, et al (2011). Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer. BJCP, 71, 737-50.
  19. Moyer AM, Suman VJ, Weinshilboum RM, et al (2011). SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics, 12, 1535-43.
  20. Ruiter R, Bijl MJ, Schaik RH, et al (2010). CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics, 11, 1367-75.
  21. Okishiro M, Taguchi T, Kim SJ, et al (2008). Genetic Polymorphisms of CYP2D6*10 and CYP2C19*2,*3 Are not Associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer, 115, 952-61.
  22. Osborne CK, (1998). Tamoxifen in the treatment of breast cancer. N Engl J Med, 339, 1609-18.
  23. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics. CA Cancer J Clin, 55, 74-108.
  24. Ruiter TR, Bijl MJ, Hofman A, et al (2009). CYP2C19*2 is associated with increased survival in breast cancer patients using tamoxifen. PDS, 18, 161-2.
  25. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603-05.
  26. Stearns V, Johnson MD, Rae JM, et al (2003). Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst, 95, 1758-64.
  27. Sukasem C, Sirachainan E, Chamnanphon M, et al (2012). Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: A Microarray-based study in Thailand. Asian Pac J Cancer Prev, 13, 4549-53.
  28. Schroth W, Antoniadou L, Fritz P, et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol, 25, 5187-93.
  29. Zafra-Ceres M, Haro TD, Farez-Vidal E, et al (2013). Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in spanish women with breast cancer. Int J Med Sci, 10, 932-37.
  30. Serrano D, Lazzeroni M, Zambon CF, et al (2011). Efficacy of tamoxifen based on cytochrome P4502D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics J, 11, 100-07.
  31. Schaik RH, Kok M, Sweep FC, et al (2011). The CYP2C19*2 genotyped predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics, 12, 1137-46.
  32. Tamminga WJ, Wemer J, Oosterhuis B et al (2001). The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol, 57, 717-22.

Cited by

  1. Effects of the CYP2C19 Genetic Polymorphism on Gastritis, Peptic Ulcer Disease, Peptic Ulcer Bleeding and Gastric Cancer vol.15, pp.24, 2015,
  2. vol.56, pp.12, 2016,
  3. protects against metabolic complications of clozapine treatment vol.18, pp.7, 2017,
  4. Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen vol.7, pp.4, 2017,
  5. and Tamoxifen Therapy vol.103, pp.5, 2018,